EDIT
NASDAQ · Biotechnology
Editas Medicine Inc
$2.75
+0.18 (+7.00%)
Analyst Consensus
Buy
19
Analysts
High
Coverage
Price Target
Analyst Price Target
+365.8% upside
Low Target
$8.62
Average Target
$12.81
High Target
$14.59
Current Price
$2.75
Current
$2.75
$2.75
Target
$12.81
$12.81
$8.62
$12.81 avg
$14.59
Scenario Analysis
Bear Case
$8.62
213.5%
Low target
Base Case
$12.81
+365.8%
Avg target
Bull Case
$14.59
+430.5%
High target
Risk/Reward
2.0x
Favorable
Price in Context
52-Week High
$3.94
-30.2% from high
52-Week Low
$1.66
+65.7% from low
Target vs 52W High
$12.81
+225.1% vs high
Peer Consensus — Biotechnology
| Stock | Consensus | Analysts | Buy % | Target | Upside |
|---|---|---|---|---|---|
| ABBV | Strong Buy | 38 | 82% | $257.58 | -12.5% |
| AMGN | Hold | 42 | 43% | $190.87 | -59.0% |
| GILD | Strong Buy | 36 | 83% | $362.68 | +115.9% |
| VRTX | Strong Buy | 39 | 82% | $438.34 | -19.2% |
| MRNA | Hold | 31 | 32% | $149.45 | -35.4% |
| REGN | Buy | 36 | 72% | $76.80 | -91.9% |
| NTRA | Strong Buy | 31 | 90% | $142.91 | -55.7% |
| RVMD | Strong Buy | 31 | 94% | $114.11 | -35.3% |